Document:

<PAGE>

                                                                  Exhibit 10.1

                           BIOTRANSPLANT INCORPORATED
                            Building 75, Third Avenue
                              Charlestown Navy Yard
                              Charlestown, MA 02129

                                 August 19, 2002

Dear Elliot,

     This letter is intended to set forth our agreements relating to the change
in your status with BioTransplant Incorporated (the "Company). As you know,
effective as of July 22, 2002, you began serving as Chairman of the Board and
you no longer served in the capacities of President and Chief Executive Officer.
You will serve as Chairman of the Board on a full-time basis until September 11,
2002 ("Termination Date"), at which point you will resign as Chairman and remain
a member of the Board of Directors.

     In connection with the foregoing, we have agreed as follows:

     1. CONTINUATION OF SALARY AND BENEFITS. Until the Termination Date, the
Company will continue to pay your monthly salary ($25,027.50) and benefits as
presently in effect. On the Termination Date, you will receive a payment for all
salary, vacation and other benefits accrued through the Termination Date. From
and after the Termination Date, you will be entitled to the severance
compensation set forth in Section 2 below.

     2. SEVERANCE PAY. From and after the Termination Date and subject to (a)
your resignation as Chairman of the Board (in the form of EXHIBIT A to this
Agreement),(b) the provisions of Section 5(b) and (c) your continuing compliance
with Sections 11, 12 and 13 below, the Company agrees to pay you in twelve (12)
equal monthly installments the total of twelve (12) months of your current base
salary (for a sum total of $300,330). The first installment of the severance
will be paid on September 30, 2002, and each subsequent installment shall be
paid on or before the last day of each month. Such severance payments shall be
in addition to the payment of all accrued obligations, such as salary, vacation
pay and benefits, up to and including the Termination Date. In the event that
the Company believes that the conditions set forth above for the payment of
severance compensation have not been satisfied (e.g., you have made disparaging
comments in violation of Section 11 or have violated the provisions of Section
13), the Company shall notify you in writing prior to suspending any payments,
which notice shall specifically identify the alleged violation. If you disagree
with the Company's belief, the issue shall be presented to a special Board
committee comprised of James Foster and Michael Perry, provided that if either
Mr. Foster or Mr. Perry are not on the Board of Directors at such time, then the
issue shall be presented to the Compensation Committee as then in effect. Both
you and the executive leadership of the Company shall have the opportunity to be
heard by the special Board committee or Compensation Committee, as applicable.
The applicable committee shall make a determination of whether the conditions to
the continuation of severance payments have been satisfied.

<PAGE>

Dr. Elliot Lebowitz
August 19, 2002
Page 2

     3. CONTINUATION OF MEDICAL INSURANCE. You will continue to participate in
the Company's medical insurance benefits plans (to the extent permitted by the
terms of the applicable benefits plans in effect at the time of termination and
subject to any employee contribution applicable to you on the Termination Date)
for a period of twelve (12) months after the Termination Date. If, however, you
are not permitted by the terms of the applicable medical insurance benefits
plans to continue to participate after the Termination Date, and if you elect
continued medical insurance coverage pursuant to COBRA, the Company will pay the
COBRA premium payments (subject to any employee contribution applicable to you
on the Termination Date) on your behalf for a period of twelve (12) months after
the Termination Date. Thereafter, the continuation of COBRA coverage will be at
your expense.

     4. STOCK OPTIONS. All outstanding stock options shall continue to vest
during the twelve (12) months following the Termination Date, and shall,
notwithstanding any provisions thereof to the contrary, remain exercisable
during such 12-months period, PROVIDED THAT if the Company suspends severance
payments due to failure by you to satisfy the conditions set forth in Section 2,
both continuation of vesting and your right to exercise the options shall
likewise terminate as of the date of such suspension.

     5. RELEASE.

        a) You hereby fully, forever, irrevocably and unconditionally release,
remise and discharge the Company, its officers, directors, stockholders,
corporate affiliates, subsidiaries, and parent companies, agents, employees, and
attorneys from any and all claims, charges, complaints, demands, actions, causes
of action, suits, rights, debts, sums of money, costs, accounts, reckonings,
covenants, contracts, agreements, promises, doings, omissions, damages,
executions, obligations, liabilities, and expenses (including attorneys' fees
and costs), of every kind and nature which you ever had or now have against the
Company, its officers, directors, stockholders, corporate affiliates,
subsidiaries and parent companies, agents, employees and attorneys up to the
date of this Agreement, arising out of your employment with or separation from
the Company including, but not limited to, all employment discrimination claims
under Title VII of the Civil Rights Act of 1964, 42 U.S.C. Section 2000e ET
SEQ., the Age Discrimination in Employment Act, 29 U.S.C. Section 621 ET SEQ.,
the Americans With Disabilities Act of 1990, 42 U.S.C. Section 12101 ET SEQ.,
and the Massachusetts Fair Employment Practices Act, M.G.L. c.151B, Section 1 ET
SEQ., and all claims arising out of the Fair Credit Reporting Act, 15 U.S.C.
Section 1681 ET SEQ., the Massachusetts Civil Rights Act, M.G.L. c. 12 Sections
11H and 11I, the Massachusetts Equal Rights Act, M.G.L. c. 93 Section 102 and
M.G.L. c. 214, Section 1C, the Massachusetts Labor and Industries Act, M.G.L. c.
149, Section 1 ET SEQ., and the Massachusetts Privacy Act, M.G.L. c. 214,
Section 1B, all as amended, and all common law claims including, but not limited
to, actions in tort, defamation and breach of contract, and any claim or damage
arising out of your employment with or separation from the Company (including a
claim for retaliation) under any common law theory or any federal, state or
local ordinance not expressly referenced above, provided, however, that nothing
in this agreement prevents you from filing, cooperating with, or participating
in any proceeding before the EEOC or a state Fair Employment Practices Agency
(except that you

<PAGE>

Dr. Elliot Lebowitz
August 19, 2002
Page 3

acknowledge that you may not be able to recover any monetary benefits in
connection with any such claim, charge or proceeding). Notwithstanding the
foregoing, it is agreed that this release does not apply to (i) any rights to
indemnification that you had or have either as an employee, officer or director
of the Company under state law, the corporate by-laws or charter of the Company
and/or pursuant to directors and officers insurance, employment practices
liability insurance or any other insurance obtained by the Company; (b) any
rights that you have as a participant in the Company's benefits plans; (c) any
rights that you have to the payment of accrued wages and benefits as of the date
of this Agreement; and (d) any rights that you have pursuant to the
Massachusetts Workers Compensation statute.

        b) As a condition precedent to the Company's obligations under Sections
2, 3 and 4 above, you and the Company agree to execute a mutual release
substantially in the forms of EXHIBIT B and EXHIBIT C, respectively, to this
Agreement below covering all claims through the Termination Date.

        c) The Company (defined to include its corporate affiliates,
subsidiaries, parent companies and agents) hereby fully, forever, irrevocably
and unconditionally releases, remises, and discharges you and your
representatives, agents, estate, heirs and assigns from any and all claims,
charges, complaints, demands, actions, causes of action, suits, rights, debts,
sums of money, costs, accountings, reckonings, covenants, contracts, agreements,
promises, doings, omissions, damages, executions, obligations, liabilities and
expenses (including attorneys' fees and costs), of every kind and nature which
the Company ever had or now has against you up to the date of this Agreement
arising out of your employment with the Company, your role as an officer and/or
director of the Company or your separation from the Company, including, but not
limited to, all statutory and common law claims of any kind.

     6. RETURN OF COMPANY PROPERTY. You agree to return all Company property and
equipment in your possession or control as of the Termination Date, including,
but not limited to, all Company files and documents. You further agree to leave
intact all electronic Company documents including those which you developed or
helped develop during your employment; provided, however, that this Section 6
does not include electronic mail (e-mail) which routinely has been deleted by
you prior to the execution of this Agreement or to any personal e-mail you
delete after the execution of this Agreement.

     7. NATURE OF AGREEMENT. The parties understand and agree that this
Agreement is a severance and settlement agreement and does not constitute an
admission of liability or wrongdoing on the part of either of the parties.

     8. AMENDMENT. This Agreement shall be binding upon the parties and may not
be abandoned, supplemented, changed or modified in any manner, orally or
otherwise, except by an instrument in writing of concurrent or subsequent date
signed by a duly authorized representative of the parties hereto. This letter
Agreement is binding upon and shall inure to the benefit of the parties and
their respective agents, assigns, heirs, executors, successors and
administrators.

<PAGE>

Dr. Elliot Lebowitz
August 19, 2002
Page 4

     9. VALIDITY. Should any provision of this Agreement be declared or be
determined by any court of competent jurisdiction to be illegal or invalid, the
validity of the remaining parts, terms, or provisions shall not be affected and
such illegal and invalid part, term or provision shall be deemed not to be a
part of this agreement.

     10. CONFIDENTIALITY. To the extent permitted by law, the parties understand
and agree that the terms and contents of this Agreement, and the contents of the
negotiations and discussions resulting in this Agreement, shall be maintained as
confidential by the parties, their agents and representatives, and none of the
above shall be disclosed except to the extent required by federal or state law
or as otherwise agreed to in writing by the authorized agent of each party.

     11. NON-DISPARAGEMENT. You understand and agree that as a condition for
payment to you of the monetary or other consideration described above, you shall
not make any disparaging or derogatory statements, in writing or orally, in
public or private regarding the Company or any of its directors or officers, or
the Company's business affairs and financial condition. In addition, the Company
agrees that neither it nor its directors and officers shall make any disparaging
or derogatory statement in public or private about you, about your performance
as an employee, officer or director of the Company or your relationship with the
Company. Notwithstanding the foregoing, nothing in this Section 11 is intended
to limit your open participation in Board meetings and your open discussions
with all other Board members.

     12. COMMUNICATIONS WITH EMPLOYEES. Other than an announcement to be
mutually agreed upon by the parties hereto and provided to employees of the
Company relating to the transition described in this agreement, neither you nor
the Company shall furnish any written communications to employees of the Company
concerning the change in the status of your relationship with the Company.

     13. COMMUNICATIONS WITH INVESTORS. Effective as of the date of this
Agreement, you agree that you will refrain from communicating with Company
investors regarding the Company, whether initiated by you or by any investor,
relating to the business, operations, personnel or prospects of the Company. If
any investor initiates contact with you regarding the Company, you agree to
refer such contact to the officer designated by the Company. In addition, you
agree that you will only represent the Company in public settings after
receiving the prior written approval of the Company's CEO to do so.
Notwithstanding the foregoing, nothing in this Section 13 is intended to limit
your open participation in Board meetings and your open discussions with all
other Board members.

     14. TRANSITION. From this date until the Termination Date, you will
continue to receive all of the same administrative support at the Company,
including support from your administrative assistant and continued use and
access to your e-mail, voicemail and regular mail. The Company understands that
you may take some vacation time from this date until the Termination Date,
solely at your discretion. The Company agrees that after the Termination Date,
the Company will assist you in the transfer of your e-mail, voicemail and
regular mail.

<PAGE>

Dr. Elliot Lebowitz
August 19, 2002
Page 5

     15. ENTIRE AGREEMENT. This Agreement contains and constitutes the entire
understanding and agreement between the parties hereto with respect to your
severance and cancels all previous oral and written negotiations, agreements,
commitments, and writings in connection therewith, including the offer letter
dated April 4, 1991. However, you acknowledge and agree that your
non-competition and confidentiality obligations set forth in the Employee
Confidential Information, Invention and Non-Competition Agreement, dated April
22, 1991, which is herein amended to reduce your non-competition restriction to
a period of one-year commencing with the date you cease to serve as a director,
remain in full force and effect, and such amended Agreement is hereby
incorporated by reference. All stock option agreements and restricted stock
agreements that you entered into with the Company, as amended herein, shall also
remain in full force and effect.

     16. INDEMNIFICATION. The Company agrees that if you are made a party or
threatened to be made a party to any action, suit or proceeding, whether civil,
criminal, administrative or investigative (a "Proceeding"), by reason of the
fact you are or were a trustee, director, officer or employee of the Company or
any subsidiary of the Company or are or were serving at the request of the
Company or any subsidiary as a trustee, director, officer, member, employee or
agent of another corporation or a partnership, joint venture, trust or other
enterprise, including, without limitation, service with respect to employee
benefit plans, whether or not the basis of such Proceeding is alleged action in
an official capacity as a trustee, director, officer, member, employee or agent
while serving as a trustee, director, officer, member, employee or agent, you
shall be indemnified and held harmless by the Company to the fullest extent
authorized by law or by the Certificate of Incorporation and By-Laws of the
Company, as the same exists or may hereafter be amended, against all expenses
(including, without limitation, attorney fees) incurred or suffered by you in
connection therewith, and such indemnification shall continue even if you cease
to be an employee, officer, director, trustee or agent, or are no longer
employed by the Company and shall inure to the benefit of your heirs, executors
and administrators. In addition, you shall be entitled to be covered by
directors and officers insurance, if any, that is obtained by the Company,
including such policies obtained after your employment has terminated.

     17. APPLICABLE LAW. This Agreement shall be governed by the laws of the
Commonwealth of Massachusetts, and is binding upon and shall inure to the
benefit of the parties and their respective agents, assigns, heirs, executors,
successors and administrators.

     18. ACKNOWLEDGMENTS. You acknowledge that you have been given twenty-one
(21) days to consider this Agreement and that the Company advised you to consult
with any attorney of your own choosing prior to signing this Agreement. You may
revoke this agreement for a period of seven (7) days after the execution of this
Agreement, and the Agreement shall not be effective or enforceable until the
expiration of this seven (7) day revocation period.

     19. VOLUNTARY ASSENT. You affirm that no other promises or agreements of
any kind have been made to or with you by any person or entity whatsoever to
cause you to sign this agreement, and that you fully understand the meaning and
intent of this agreement. You state and represent that you have had an
opportunity to fully discuss and review the terms of this agreement with an
attorney. You further state and represent that you have carefully read this

<PAGE>

Dr. Elliot Lebowitz
August 19, 2002
Page 6

agreement, understand the contents herein, freely and voluntarily assent to all
of the terms and conditions hereof, and sign your name of your own free act.

     If the foregoing accurately reflects our mutual agreement, please so
indicate by countersigning this letter in the space provided below.

     If you have any questions, please do not hesitate to call me. Thank you for
your valuable contributions to the Company over these years.

                                     Sincerely,

                                     BIOTRANSPLANT INCORPORATED

                                     By: /s/ Donald Hawthorne
                                         -------------------------------------
                                         Donald Hawthorne
                                         President and Chief Executive Officer

AGREED:

/s/ Elliot Lebowitz
--------------------------------
Elliot Lebowitz

<PAGE>

                                    EXHIBIT A

                           FORM OF RESIGNATION LETTER

                                                     September 11, 2002

To the BioTransplant Board of Directors:

         Effective as of the close of business on September 11, 2002, I hereby
resign as Chairman of the Board of Directors of BioTransplant Incorporated.

                                   Sincerely,

                                   Dr. Elliot Lebowitz

<PAGE>

                                    EXHIBIT B

                          FORM OF DR. LEBOWITZ RELEASE

     Reference is made to the agreement dated as of August 19, 2002 (the
"Agreement") between the undersigned and BioTransplant Incorporated (the
"Company"). Pursuant to Section 5(b) of the Agreement, and in consideration of
the payments to be made by the Company pursuant to the Agreement, the
undersigned fully, forever, irrevocably and unconditionally releases, remises
and discharges the Company, its officers, directors, stockholders, corporate
affiliates, subsidiaries, and parent companies, agents, employees, and attorneys
from any and all claims, charges, complaints, demands, actions, causes of
action, suits, rights, debts, sums of money, costs, accounts, reckonings,
covenants, contracts, agreements, promises, doings, omissions, damages,
executions, obligations, liabilities, and expenses (including attorneys' fees
and costs), of every kind and nature which the undersigned ever had or now has
against the Company, its officers, directors, stockholders, corporate
affiliates, subsidiaries and parent companies, agents, employees and attorneys
up to the date of this Release, arising out of the undersigned's employment with
or separation from the Company including, but not limited to, all employment
discrimination claims under Title VII of the Civil Rights Act of 1964, 42 U.S.C.
Section 2000e ET SEQ., the Age Discrimination in Employment Act, 29 U.S.C.
Section 621 ET SEQ., the Americans With Disabilities Act of 1990, 42 U.S.C.
Section 12101 ET SEQ., and the Massachusetts Fair Employment Practices Act,
M.G.L. c.151B, Section 1 ET SEQ., and all claims arising out of the Fair Credit
Reporting Act, 15 U.S.C. Section 1681 ET SEQ., the Massachusetts Civil Rights
Act, M.G.L. c. 12 Sections 11H and 11I, the Massachusetts Equal Rights Act,
M.G.L. c. 93 Section 102 and M.G.L. c. 214, Section 1C, the Massachusetts Labor
and Industries Act, M.G.L. c. 149, Section 1 ET SEQ., and the Massachusetts
Privacy Act, M.G.L. c. 214, Section 1B, all as amended, and all common law
claims including, but not limited to, actions in tort, defamation and breach of
contract, and any claim or damage arising out of the undersigned's employment
with or separation from the Company (including a claim for retaliation) under
any common law theory or any federal, state or local ordinance not expressly
referenced above, provided, however, that nothing in this agreement prevents the
undersigned from filing, cooperating with, or participating in any proceeding
before the EEOC or a state Fair Employment Practices Agency (except that the
undersigned acknowledges that he may not be able to recover any monetary
benefits in connection with any such claim, charge or proceeding).
Notwithstanding the foregoing, it is agreed that this release does not apply to
(i) any rights to indemnification that the undersigned had or has either as an
employee, officer or director of the Company under state law, the corporate
by-laws or charter of the Company and/or pursuant to directors and officers
insurance, employment practices liability insurance or any other insurance
obtained by the Company; (b) any rights that the undersigned has as a
participant in the Company's benefits plans; (c) any rights that the undersigned
has to the payment of accrued wages and benefits as of the date of this Release;
and (d) any rights that the undersigned has pursuant to the Massachusetts
Workers Compensation statute.

     EXECUTED as a sealed instrument as of September 11, 2002.

                                               ---------------------------------
                                               Dr. Elliot Lebowitz

<PAGE>

                                    EXHIBIT C

                             FORM OF COMPANY RELEASE

         Reference is made to the agreement dated as of August 19, 2002 (the
"Agreement") between BioTransplant Incorporated (the "Company") and Dr. Elliot
Lebowitz ("Dr. Lebowitz"). Pursuant to Section 5(b) of the Agreement, the
Company (defined to include its corporate affiliates, subsidiaries, parent
companies and agents) hereby fully, forever, irrevocably and unconditionally
releases, remises, and discharges Dr. Lebowitz and his representatives, agents,
estate, heirs and assigns from any and all claims, charges, complaints, demands,
actions, causes of action, suits, rights, debts, sums of money, costs,
accountings, reckonings, covenants, contracts, agreements, promises, doings,
omissions, damages, executions, obligations, liabilities and expenses (including
attorneys' fees and costs), of every kind and nature which the Company ever had
or now has against Dr. Lebowitz up to the date of this Release arising out of
Dr. Lebowitz' employment with the Company, his role as an officer and/or
director of the Company or his separation from the Company, including, but not
limited to, all statutory and common law claims of any kind.

         EXECUTED as a sealed instrument as of September 11, 2002.

                                      BIOTRANSPLANT INCORPORATED

                                      By:  ____________________________________
                                           Donald Hawthorne
                                           President and Chief Executive OfficerExhibit 10.102  

Dated as of August 8, 2002 

Letter Agreement  

The
Immune Response Corporation

5935 Darwin Court

Carlsbad, CA 92008

Attention: Michael L. Jeub 

Re:
Nasdaq Compliance Restrictions

Dear
Michael: 

        The
undersigned, each a security holder and an affiliate of a director of The Immune Response Corporation, a Delaware corporation (the "Company"), understand that the Nasdaq National
Market ("Nasdaq") has contacted the Company regarding an alleged violation of National Association of Security Dealers ("NASD") Rule 4350(i)(1)(A) (the "Insider Rule"),
Rule 4350(i)(1)(B) (the "Change in Control Rule") and Rule 4350(i)(1)(D) (the "20% Rule") in connection with the sale of Notes and Warrants to the undersigned pursuant to the Note
Purchase Agreement dated as of November 9, 2001, by and between the Company and the Kevin Kimberlin Partners, L.P., a Delaware limited partnership ("KKP"), as amended by Amendment No. 1
to the Note Purchase Agreement dated as of February 14, 2002, Amendment No. 2 to the Note Purchase Agreement, dated as of May 3, 2002, each by and between the Company, KKP and
Oshkim Limited Partnership, a Nevada limited partnership ("Oshkim") and Amendment No. 3 to the Note Purchase Agreement, dated as of July 11, 2002, by and between the Company, KKP, Oshkim
and The Kimberlin Family 1998 Irrevocable Trust (the "Agreement"). While neither the Company nor the undersigned believe that the transactions pursuant to the Agreement violated the Insider Rule, the
Change in Control Rule or the 20% Rule, all parties agree that, as requested by Nasdaq in order to ensure compliance with the Insider Rule, it is in the
best interest of the Company and the undersigned to agree to certain restrictions with respect to the Common Stock of the Company underlying the Notes and Warrants issued in May, June and July, 2002,
pursuant to the Agreement. 

        In
recognition of the benefit that continued listing of the Company's Common Stock on Nasdaq would confer upon the undersigned as security holders of the Company and to enable the
Company and the undersigned to engage in future financing pursuant to the Agreement, the undersigned and the Company agree that until either (i) the Company obtains stockholder approval (which
approval the Company shall use its best efforts to obtain by November 30, 2002) of the transactions for purposes of compliance with the Insider Rule, the Change in Control Rule and the 20% Rule
or (ii) at such time as a proposed merger, sale of assets or similar transaction, or tender or exchange offer is under consideration by our Board of Directors, the restrictions will lapse, the
undersigned will not, without the prior written consent of the Company, directly or indirectly: 

          (i)  vote
any shares of the Common Stock issuable upon the conversion or exercise of the respective Notes and Warrants issued in May, June and July, 2002; 

        (ii)  offer,
pledge, sell, or otherwise dispose of or transfer any shares of the Common Stock issuable upon the conversion or exercise of the respective Notes and Warrants
issued in May, June and July, 2002; 

        (iii)  receive
any additional shares of capital sock (or securities convertible into or exchangeable for capital stock) issuable by the Company via a stock dividend or stock
distribution paid with respect to its Common Stock ("Dividends") issuable upon the conversion or exercise of the respective Notes and Warrants issued in May, June and July, 2002; 

        (iv)  convert
or exercise any of the respective Notes and Warrants issued in May, June and July, 2002. 

        Notwithstanding
subsection (ii), the undersigned may transfer or assign shares of the Common Stock issuable upon the conversion or exercise of the respective Notes and Warrants issued
pursuant to the Agreement (i) as a bona fide gift or gifts, provided that the donee or donees thereof enter into a Letter Agreement on terms identical to the terms of this Letter Agreement, or
(ii) to any trust for the direct or indirect benefit of the undersigned, provided that the trustee of the trust enter into a Letter Agreement on terms identical to the terms of this Letter
Agreement, and provided further that any such transfer shall not involve a disposition for value. In addition, notwithstanding the foregoing, the undersigned may transfer or assign the capital stock
of the Company to any partner of the undersigned or affiliate of such partner; provided, however, that in any such case, it shall be a condition to the transfer or assignment that the transferee or
assignee enter into a Letter Agreement on terms identical
to the terms of this Letter Agreement and there shall be no further transfer of such capital stock except in accordance with this Letter Agreement, and provided further that any such transfer shall
not involve a disposition for value. The undersigned also agrees and consents to the entry of stop transfer instructions with the Company's transfer agent and registrar against the transfer of the
undersigned's securities except in compliance with the foregoing restrictions. 

        Notwithstanding
subsection (iii), any Dividends which the undersigned would have the right to receive shall be held in escrow for the undersigned by the Chief Financial Officer of the
Company until obtaining stockholder approval for the transaction for purposes of compliance with the Insider Rule, the Change in Control Rule or the 20% Rule. 

	 	 	Very truly yours,
	

 	
 	

OSHKIM LIMITED PARTNERSHIP
	

 	
 	

	 	 	By:	 	 
	 	 	Its:	 	 
	

 	
 	

THE KIMBERLIN FAMILY 1998 IRREVOCABLE TRUST
	

 	
 	

	 	 	By:	 	 
	 	 	Its:	 	 
	

Agreed and accepted:	
 	

 	
 	

 
	

THE IMMUNE RESPONSE CORPORATION	
 	

 	
 	

 
	

 Michael L. Jeub

Vice President, Finance and Chief Financial Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00045-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00045-of-00352.parquet"}]]